Clinical Trial Update: A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for ALLO-329, an allogeneic CAR T-cell therapy, in adults with autoimmune diseases including systemic lupus erythematosus, idiopat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Inflammatory Myopathy
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• ALLO-329 (ALLO-329)

Snippet

Sponsor: Allogene Therapeutics | Conditions: Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy | Phase 1 | Status: RECRUITING